OB/GYN Clinical Alert – July 1, 2007
July 1, 2007
View Issues
-
Pharmacology Watch: Avandia, Risk of Congestive Heart Failure Significant Safety Risk
Aspirin, Higher Doses No More Effective, Risky; Subclinical Hypothyroidism Treatment Benefits; FDA approvals -
Clinical Briefs in Primary Care supplement
-
Postmenopausal Hormone Therapy and Ovarian Cancer
The Million Women Study reported a small increase in the incidence of ovarian cancer and ovarian cancer mortality in current users of postmenopausal hormone therapy. -
Special Feature: Understanding Hormone Action: Does Route of Administration Matter?
Until recently, available information supported the notion that the transdermal route of administration of estradiol has less hepatic impact than the oral route. -
The FUTURE of Cervix Cancer Prevention?
Human Papilloma Virus (HPV) is recognized worldwide as the principal culprit in the development of cervix cancer and its precursor dysplastic lesions. Also increasingly recognized is its role in other anogenital disease such as vulvar, vaginal and perianal warts, dysplasia and cancer. -
Cervical Length Changes During Preterm Cervical Ripening: Effect of 17-á- Hydroxyprogesterone Caproate
In the May issue of the American Journal of Obstetrics and Gynecology, there was a report of a small randomized trial that might generate some cautious optimism regarding the treatment of PTL. -
Hepatitis C and Menopause
Codes and colleagues from France followed a cohort of 251 women with chronic hepatitis C, and report data associating the severity of fibrosis established by liver biopsies with menopause and hormone therapy.